Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pneumococcal Polysaccharide Vaccine 23-valent (AIM Honesty)
- Development stage
- Preclinical
- Lead developer
- AIM Vaccine Co.
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This 23-valent pneumococcal polysaccharide vaccine (PPSV23) is an investigational vaccine being developed by AIM Honesty (also known as AIM Bio) for the prevention of pneumococcal disease. The vaccine is formulated with purified capsular polysaccharide antigens from 23 distinct serotypes of *Streptococcus pneumoniae*. Its mechanism of action involves stimulating the immune system to produce protective, serotype-specific antibodies that help prevent invasive infections such as pneumonia, meningitis, and bacteremia. According to company pipeline information, the vaccine is currently in the preclinical development stage.
- Other names
- 23-valent pneumococcal polysaccharide vaccinePPSV23 (AIM Honesty)
Beyond the preview
Go deeper on Pneumococcal Polysaccharide Vaccine 23-valent (AIM Honesty).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pneumococcal Polysaccharide Vaccine 23-valent (AIM Honesty).